PMID- 31692488
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220411
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 11
DP  - 2019
TI  - Comprehensive assessment of HER2 alteration in a colorectal cancer cohort: from 
      next-generation sequencing to clinical significance.
PG  - 7867-7875
LID - 10.2147/CMAR.S213247 [doi]
AB  - PURPOSE: Human epidermal growth factor receptor 2 (HER2) is an emerging 
      therapeutic target in colorectal cancer (CRC). Currently, immunohistochemistry 
      (IHC) and fluorescence in situ hybridization (FISH) have been used to determine 
      HER2-positive CRCs; however, the clinical utility of next-generation sequencing 
      (NGS)-based techniques for determining HER2 status in CRC has been limited. Here, 
      we detail our experience regarding the assessment of HER2 alterations in a CRC 
      cohort. MATERIALS AND METHODS: We prospectively enrolled 73 CRC patients who 
      underwent surgery and received adjuvant oxaliplatin treatment. We then examined 
      HER2 alterations using the Oncomine Comprehensive Assay version 1, as well as 
      clinical outcomes, in this cohort. RESULTS: Using the NGS-based assay, HER2 copy 
      number gains in 12 of 73 CRCs were determined to range from 2.74 to 92.62. Of 
      these 12 tumors, 6 had HER2 high-level copy number gain (92.6, 57.9, 57.0, 52.0, 
      35.2, and 8.42) and were all defined as HER2-positive CRC using HERACLES 
      Diagnostic Criteria. Nevertheless, other 6 patients with low-level copy number 
      gain (ranging from 2.74 to 3.04) and the remaining 61 patients without increase 
      in HER2 copy number were all HER2-negative. Among the 6 HER2-positive CRCs, KRAS 
      and PIK3CA mutations were detected in 1 (17%; G13D) and 2 (33.3%; 1 Q546R and 1 
      H1047R) patients, respectively. Moreover, 2 of the 6 (33.3%) HER2-positive 
      patients had recurrent disease, while one patient had a partial response after 
      anti-HER2 therapy. CONCLUSION: NGS-based tools could assist in the simultaneous 
      detection of HER2 and other genomic alterations in patients with CRC. Only CRCs 
      with HER2 high-level copy number gain were HER2-postive by current diagnostic 
      criteria.
CI  - (c) 2019 Yeh et al.
FAU - Yeh, Yu-Min
AU  - Yeh YM
AD  - Graduate Institute of Clinical Medicine, National Cheng Kung University Hospital, 
      College of Medicine, National Cheng Kung University, Tainan City, Taiwan.
AD  - Department of Internal Medicine, National Cheng Kung University Hospital, College 
      of Medicine, National Cheng Kung University, Tainan City, Taiwan.
FAU - Lee, Chun-Hui
AU  - Lee CH
AD  - Department of Internal Medicine, National Cheng Kung University Hospital, College 
      of Medicine, National Cheng Kung University, Tainan City, Taiwan.
FAU - Chen, Shang-Hung
AU  - Chen SH
AD  - Department of Internal Medicine, National Cheng Kung University Hospital, College 
      of Medicine, National Cheng Kung University, Tainan City, Taiwan.
AD  - National Institute of Cancer Research, National Health Research Institutes, 
      Hsinchu, Taiwan.
FAU - Lee, Chung-Ta
AU  - Lee CT
AD  - Department of Pathology, National Cheng Kung University Hospital, College of 
      Medicine, National Cheng Kung University, Tainan City, Taiwan.
FAU - Chen, Yi-Lin
AU  - Chen YL
AD  - Department of Pathology, National Cheng Kung University Hospital, College of 
      Medicine, National Cheng Kung University, Tainan City, Taiwan.
FAU - Lin, Bo-Wen
AU  - Lin BW
AD  - Division of Colorectal Surgery, Department of Surgery, National Cheng Kung 
      University Hospital, College of Medicine, National Cheng Kung University, Tainan 
      City, Taiwan.
FAU - Lin, Shao-Chieh
AU  - Lin SC
AD  - Division of Colorectal Surgery, Department of Surgery, National Cheng Kung 
      University Hospital, College of Medicine, National Cheng Kung University, Tainan 
      City, Taiwan.
FAU - Chan, Ren-Hao
AU  - Chan RH
AD  - Division of Colorectal Surgery, Department of Surgery, National Cheng Kung 
      University Hospital, College of Medicine, National Cheng Kung University, Tainan 
      City, Taiwan.
FAU - Lee, Jenq-Chang
AU  - Lee JC
AD  - Division of Colorectal Surgery, Department of Surgery, National Cheng Kung 
      University Hospital, College of Medicine, National Cheng Kung University, Tainan 
      City, Taiwan.
FAU - Shen, Meng-Ru
AU  - Shen MR
AD  - Department of Pharmacology, National Cheng Kung University Hospital, College of 
      Medicine, National Cheng Kung University, Tainan City, Taiwan.
AD  - Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, 
      College of Medicine, National Cheng Kung University, Tainan City, Taiwan.
FAU - Lin, Peng-Chan
AU  - Lin PC
AD  - Department of Internal Medicine, National Cheng Kung University Hospital, College 
      of Medicine, National Cheng Kung University, Tainan City, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20190820
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC6708395
OTO - NOTNLM
OT  - HER2
OT  - PIK3CA
OT  - colorectal cancer
OT  - next generation sequencing
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/11/07 06:00
MHDA- 2019/11/07 06:01
PMCR- 2019/08/20
CRDT- 2019/11/07 06:00
PHST- 2019/04/24 00:00 [received]
PHST- 2019/08/06 00:00 [accepted]
PHST- 2019/11/07 06:00 [entrez]
PHST- 2019/11/07 06:00 [pubmed]
PHST- 2019/11/07 06:01 [medline]
PHST- 2019/08/20 00:00 [pmc-release]
AID - 213247 [pii]
AID - 10.2147/CMAR.S213247 [doi]
PST - epublish
SO  - Cancer Manag Res. 2019 Aug 20;11:7867-7875. doi: 10.2147/CMAR.S213247. 
      eCollection 2019.